SESSION TITLE: Lung Cancer Posters II
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: Rare tumors of the lung and mediastinum account for less than 1% of all thoracic tumours and only few data are reported on their clinical behavior, diagnosis, treatment and prognosis. The goal of this study was to review a Pulmology service experience with rare thoracic tumors, in a 3 years period.
METHODS: Retrospective analysis of the clinical reports of all rare thoracic tumors diagnosed between 2010 and 2012, in our Pulmonary unit.
RESULTS: 20 tumors were diagnosed, 7 located to mediastinum (1 angiosarcoma, 1 lipoma, 1 schwanoma, 2 thymoma, 1 paraganglioma, 1 small-cell neuroendocrine tumor) and 13 to the lung (2 synovialsarcoma, 2 typical carcinoid tumor, 1 adenoid cystic carcinoma, 1 sclerosing haemangioma, 1 leiomyosarcoma, 1 large-cell neuroendocrine carcinoma, 1 MALT lymphoma, 1 Hodgking lymphoma, 1 schwanoma, 1 carcinosarcoma, 1 pleiomorphic sarcoma). All cases already evidenced changes in the X-ray and the presence of a mass was the most common finding (80%). Endoscopic changes were observed in 6 cases, with signs of extrinsic compression of the airways (2), areas of infiltration (2) or endobronchial lesions (2). All transthoracic biopsies were inconclusive and in most patients (80%) the diagnosis was established by surgery. In 50 % of cases, more than one approach for histological diagnosis was required. Surgery was the treatment modality in 60% of the cases, with a complete resection in 92%. 7 patients were submitted to chemotherapy (QT) and 1 to QT and radiation. 7 patients died, all from progression of the disease, with a mean survival of 13 months after the diagnosis.
CONCLUSIONS: In the last 3 years, 17 different histological types of rare tumors were diagnosed, with diverse presentations, malignancy behaviors and prognosis. This findings highlight a significant number of rare tumors in a small period of time, which can result from a better recognition of their features in the last years.
CLINICAL IMPLICATIONS: Our experience is a contribute for a better understanding of these rare entities.
DISCLOSURE: The following authors have nothing to disclose: Marta Sousa, Vitor Melo, Eloisa Silva, Jorge Vale, João Silva, Bárbara Rodrigues, António Torres
No Product/Research Disclosure Information